Matthijs van Haren
Chief Scientific Officer Cantoni Therapeutics
Seminars
Wednesday 1st October 2025
Panel Discussion: Exploring Pathways in Obesity Treatment From Inflammation to RNA & Hypothalamic Precision
5:30 pm
- Targeting inflammation to restore metabolic homeostasis and leverage dual action therapies for metabolic restoration and reduction in chronic inflammation
- Promoting adipose browning and lean mass retention through RNA-Based miR-22 inhibition for fat remodelling and improved body composition
Wednesday 1st October 2025
Inhibition of NNMT as a Novel, Non-Incretin Based, Treatment Option for Obesity & Its Co-Morbidities
4:00 pm
- Evaluating the inhibition of Nicotinamide N-methyltransferase (NNMT) to regulate the epigenetic metabolome and target the underlying dysfunctional biology of obesity
- Overcoming the limitations of substrate-dependent inhibition with a bisubstrate approach to ensure independent binding, ensuring potent and predictable target engagement
- Unlocking durable weight loss and metabolic health through NNMT inhibition to drive significant reductions in adiposity to improve insulin sensitivity and normalise blood glucose level
